Every 10-Q that Telomir Pharmaceuticals, Inc. (TELO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.
Telomir Pharmaceuticals, Inc. reported a net loss of $1.7 million for the quarter and $2.7 million for the six months ended June 30, 2026, with no revenue as it remains a clinical-stage oncology company focused on its lead candidate Telomir-Zn. Cash was $5.2 million and stockholders’ equity $5.0 million, down from $7.3 million of cash and $5.9 million of equity at December 31, 2025.
Management discloses that these cash resources, combined with ongoing losses and expected spending, raise substantial doubt about the company’s ability to continue as a going concern over the 12 months following issuance, and additional external financing is needed to fund operations and clinical trials. Telomir completed a related-party merger with TELI Pharmaceuticals on April 22, 2026, issuing 34,389,710 shares of common stock to acquire worldwide intellectual property rights to Telomir-Zn; because the acquired net assets had a historical carrying value of zero apart from a $1.0 million cash contribution, the transaction generated a $46.1 million deemed dividend and roughly doubled shares outstanding to 68,774,956.
Operating expenses decreased sharply year over year, with general and administrative costs for the first half of 2026 falling to $1.9 million from $6.9 million, largely due to lower stock-based compensation, while research and development rose to $0.9 million as Telomir-Zn advanced. The company has FDA clearance of an Investigational New Drug application for a trial in advanced or metastatic triple-negative breast cancer and has a binding related-party funding commitment of up to $4.0 million tied to future Telomir-Zn regulatory and clinical milestones, alongside an unused $5.0 million related-party credit line.
Telomir Pharmaceuticals reported a Q1 2026 net loss of $0.99 million with no revenue, reflecting its early-stage biotech focus on Telomir-1 (Telomir-Zn) for cancer and age-related diseases. Operating costs were $1.04 million, with general and administrative expenses falling sharply year over year as prior stock-based compensation stepped down, while research and development rose modestly as preclinical and clinical work progressed.
Cash was $5.6 million as of March 31, 2026 after using about $1.8 million in operating cash during the quarter, leaving stockholders’ equity of roughly $5.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without new capital. After quarter-end, Telomir closed its merger with related-party TELI Pharmaceuticals, issuing 34,389,710 restricted shares and securing a $1.0 million cash contribution plus a binding commitment for up to an additional $4.0 million tied to Telomir-1 development milestones. A small at-the-market sale added about $6,000 of proceeds.
Telomir Pharmaceuticals (NASDAQ: TELO) filed its Q3 2025 10‑Q, reporting ongoing preclinical development and continued losses. Net loss was $1.1 million for the quarter and $8.4 million year‑to‑date, with no revenue. Operating costs in Q3 were $1.15 million, driven by $0.76 million in R&D and $0.39 million in G&A.
Cash rose to $7.33 million as of September 30, 2025, supported by financings: $5.55 million in ATM proceeds during the nine months and a $3.0 million related‑party equity investment at a premium. Subsequent to quarter end, the company raised an additional $1.00 million via ATM block sales. The company disclosed substantial doubt about its ability to continue as a going concern despite indicating current cash is expected to fund operations through the third quarter of 2026.
Shares outstanding were 33,830,971 at September 30, 2025 and 34,380,971 as of November 7, 2025. Telomir executed a binding LOI on October 17, 2025 to acquire TELI Pharmaceuticals, aiming to consolidate worldwide rights to Telomir‑1, with up to $5 million in potential shareholder contributions tied to milestones, subject to approvals.